Morgan Group Holding Co. (MGHL)
OTC PINK OTC PINK Primary 
Morgan Stanley Slashes Lucid Price Target in Half: Stop-Sale, CEO Hunt Spell Deep Trouble
Lucid Group (NASDAQ:LCID | LCID Price Prediction) saw its Morgan Stanley price target cut in half to $5 from $10 on May 6, with the firm keeping its Underweight rating.
JP Morgan raises Standard Chartered target ahead of investor day as bank targets 15% returns
Standard Chartered PLC (LSE:STAN) shares are in focus ahead of a closely watched investor day on 19 May, with JP Morgan raising its price target on the emerging markets-focused bank and flagging expectations of ambitious new profitability targets to 2028. Analyst Kian Abouhossein, who carries an overweight rating on the stock, lifted his price target to 2,220p from 2,200p after increasing earnings per share estimates by 2-3%, driven by stronger revenues and lower costs in his model.
Morgan Stanley Lifts IonQ Price Target to $47: Is the Quantum Computing Stock Finally Ready to Deliver?
Morgan Stanley raised its price target on IonQ (NYSE:IONQ | IONQ Price Prediction) to $47 from $37, while keeping an Equal Weight rating.
Morgan Stanley Doubles Caterpillar Price Target to $915: Is This the Most Underrated Industrial of 2026?
Morgan Stanley raised its price target on Caterpillar (NYSE:CAT | CAT Price Prediction) to $915 from $430, while upgrading the stock to Equal Weight from Underweight.
Why is Morgan Stanley bullish on 2 SaaS stocks everyone sold?
The software sell-off of early 2026 did not happen because earnings suddenly fell apart. It happened because investors started to wonder whether AI could make big chunks of traditional SaaS less valuable, or even obsolete.
Energy Transfer vs. Kinder Morgan: Which Energy Stock Is a Better Bet?
KMI tops ET, its midstream rival with stronger price gains, improving earnings outlook and lower debt use.
JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limited
Bank sits 5-10% below consensus on core earnings from 2027, citing need for pipeline success and new launch execution JP Morgan has retained its underweight rating on GSK PLC (LSE:GSK, NYSE:GSK) with a June 2027 price target of £17, arguing that near-term earnings upgrade potential is limited and that the pharmaceutical group's longer-term outlook remains contingent on pipeline success and the execution of new product launches. Analyst Zain Ebrahim made modest forecast changes following GSK's first-quarter 2026 results, including foreign exchange-related adjustments of 0% to 1% to sales forecasts across 2026 to 2031 and upgrades of 1% to 2% to core operating profit estimates.
Kinder Morgan: A Top Income Pick For 2026
Kinder Morgan delivered strong Q1 '26 results, with EBITDA up 18% and a $10B expansion backlog, driven by robust natural gas demand. KMI's natural gas segment, supported by fee-based contracts, underpins earnings growth and a dividend coverage ratio estimated at 2.72X for Q1 '26. Shares trade at 11.9X EV/EBITDA, below the industry average, implying 7.1% revaluation potential and a fair value target of $34 per share.
Morgan Stanley Supports Stablecoin Issuers With New Fund for Reserves
Morgan Stanley Investment Management (MSIM) has launched a new government money market fund designed to meet the needs of payment stablecoin issuers that are looking to invest the reserves that back their outstanding payment stablecoins.
Morgan Stanley Downgrades Freeport-McMoRan: Is the Copper Story Breaking Down at Grasberg?
Morgan Stanley downgraded Freeport-McMoRan (NYSE:FCX | FCX Price Prediction) to Equal Weight from Overweight and cut its price target to $66 from $70, pointing to a slower production ramp at the company's Grasberg Block Cave mine in Indonesia.
Kinder Morgan's Cash Flow Drives Upside: Potential Swells in Q1
Kinder Morgan NYSE: KMI is well-positioned as a leading middleman for natural gas markets. While its business is diversified across energy markets, the focus is on natural gas, and demand is swelling.
Kinder Morgan: Thank Storm Fern And All Of The Cold Weather After That
Kinder Morgan delivered a standout Q1. KMI's earnings surge is nonrecurring. Guidance remains unchanged.
